Company intelligence / Profile preview
Autobahn Therapeutics
San Diego, California, United Statesautobahntx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ABX-002 was generally well-tolerated in Phase 1 program. The company has initiated Phase 2 trials for ABX-002 as an adjunctive treatment for major depressive disorder and bipolar disorder depression. The Phase 2 open-label trial for bipolar depression will study ABX-002 in 30 adult patients with depressive episodes associated with bipolar I and bipolar II disorder, utilizing neuroimaging assessments and validated clinical scales.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesprodrugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Autobahn Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autobahn Therapeutics.